Status:
COMPLETED
B Cell Induction in Pediatric Lung Transplantation
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Clinical Trials in Organ Transplantation in Children
Rho Federal Systems Division, Inc.
Conditions:
Lung Transplant
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE2
Brief Summary
In this study, doctors are trying to see if a study drug called rituximab (Rituxan®) will lower the number of B cells in the body. Doctors are also trying to see if decreasing B cells with rituximab (...
Detailed Description
Patients who receive a lung transplant are at risk for rejection of the transplanted lung(s). Rejection occurs when the new lung triggers the body's defense (immune) system. When the immune system is ...
Eligibility Criteria
Inclusion
- Enrollment:
- Subject and/or parent guardian must be able to understand and provide informed consent;
- Candidate for a primary lung transplant (listed for lung transplant);
- Female and male subjects with reproductive potential must agree to use FDA approved methods of birth control for 12-months after completion of treatment.
- Adequate bone marrow functions based on the following criteria:
- Absolute neutrophil count (ANC): \>1000mm\^3
- Platelets: \>100,000/mm\^3
- Hemoglobin: \>7 gm/dL
- AST or ALT\< 2x Upper Limit of Normal unless related to primary disease
- Randomization:
- Individuals who meet all of the following criteria are eligible for randomization:
- Serum IgG immunoglobulin level greater than lower level of normal for age based on local laboratory ranges or 400mg/dL within 90 days prior to randomization;
- Female subjects of childbearing potential must have a negative pregnancy test within 4 hours of transplant;
- Negative for Hepatitis B infection (if at time of transplant, participant does not exhibit effective immunization, the participant should be re-tested).
Exclusion
- Enrollment:
- Individuals who meet any of these criteria are not eligible for enrollment as study participants:
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol;
- Multi-organ transplant;
- Previous treatment with rituximab (Rituxan®);
- History of severe allergic anaphylactic reactions to humanized or murine monoclonal antibodies;
- History of severe reaction to previous therapy with intravenous immunoglobulin (IVIG);
- History of Burkholderia cenocepacia;
- History of anti-CD20 therapy;
- Persistent hypogammaglobulinemia (IgG \< lower level of normal for age based on local laboratory ranges or 400 gm/dL for \>2 months) and/or IVIG replacement therapy;
- Positive blood culture, sepsis or other disease process with hemodynamic instability at time of enrollment;
- Any history of serologic positivity to HIV, HBsAg, HBcAb and HCV Ab;
- History of malignancy less than 2 years in remission of malignancy (any history of adequately treated in-situ cervical carcinoma, or adequately treated basal or squamous cell carcinoma of the skin will be permitted);
- Any condition, including psychiatric disorders, that in the opinion of the investigator would interfere with the subject's ability to comply with study requirements;
- Participation in another investigational trial within 4 weeks of enrollment;
- Currently lactating or plans to become pregnant during the timeframe of the study follow-up period;
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
- Randomization:
- Individuals who meet any of these criteria are not eligible for randomization:
- Use of an induction agent other than Thymoglobulin®;
- Renal insufficiency requiring hemodialysis or ultrafiltration;
- Inability to obtain intravenous access;
- Positive blood culture, sepsis or other disease process with hemodynamic instability at time of transplant;
- Use of investigational agent(s) within 5 half-lives of the investigational drug or 4 weeks, whichever is longer;
- Receipt of a MMR vaccine within 30 days prior to randomization;
- Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements.
Key Trial Info
Start Date :
January 22 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2019
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT02266888
Start Date
January 22 2015
End Date
June 30 2019
Last Update
October 26 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Palo Alto, California, United States, 94305
2
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
3
Washington University
St Louis, Missouri, United States, 63110
4
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229